Cabaletta Bio, Inc. — Q2 2020 Form 10-Q Summary
Business context and reporting period
Cabaletta Bio is a clinical-stage biotechnology company developing engineered CAAR T-cell therapies for B-cell-mediated autoimmune diseases. This report covers the three and six months ended June 30, 2020, filed August 6, 2020. The company’s lead candidate, DSG3-CAART, received FDA orphan drug designation in January 2020 and fast track designation in May 2020; the Phase 1 DesCAARTes trial was initiated in June 2020.
Financial condition and key metrics
| Metric | Three months ended June 30 | Six months ended June 30 |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $5.3 million, versus $2.7 million | $10.0 million, versus $5.4 million |
| General and administrative expense | $2.9 million, versus $1.1 million | $6.1 million, versus $2.4 million |
| Total operating expenses | $8.2 million, versus $3.8 million | $16.1 million, versus $7.8 million |
| Net loss | $8.2 million, versus $3.4 million | $15.6 million, versus $6.9 million |
| Loss per share | $0.35, versus $1.87 | $0.68, versus $7.48 |
| Net cash used in operating activities | $12.6 million for the six months, versus $6.1 million |
The company had $112.1 million of cash and cash equivalents, $11.1 million of available-for-sale investments and total liquidity of $123.2 million at June 30, 2020. Total assets were $127.9 million, current liabilities were $3.3 million and stockholders’ equity was $124.6 million. Accumulated deficit was $48.6 million. The filing does not report funded debt or a credit facility; management states that it has no credit facility or committed sources of capital.
Gross margins and operating margins are not meaningful because the company has no product revenue. The six-month cash decrease was $24.1 million, consisting of $12.6 million used in operations, $11.3 million used in investing activities and $0.2 million used in financing activities. Investing outflows primarily reflected $11.1 million of purchases of corporate bonds.
Material changes versus the prior comparable period
- Six-month research and development expense increased $4.5 million, primarily from higher personnel costs, manufacturing and vector-development costs, preclinical development services and initial DesCAARTes trial expenses.
- Six-month general and administrative expense increased $3.8 million due mainly to additional personnel, stock-based compensation, public-company insurance and professional services.
- Six-month net loss increased $8.7 million. Interest income declined by $0.5 million despite higher cash balances because of lower interest rates.
- Cash and cash equivalents declined from $136.2 million at December 31, 2019 to $112.1 million at June 30, 2020, while investments increased from zero to $11.1 million.
- The company entered into amendments with Penn and CHOP in May 2020, including expanded sponsored research, additional intellectual property and increased CAROT-related commitments. The sponsored research plan through February 2023 has an estimated total cost of $11.8 million.
Guidance, outlook, commentary and risks
Management expects operating losses and research and development spending to increase substantially as clinical and preclinical programs advance. It states that cash, cash equivalents and investments at June 30, 2020 should fund operations for at least 12 months following the financial statements, while the MD&A estimates funding through at least the third quarter of 2022 under the current operating plan. These estimates depend on assumptions that may prove incorrect, and additional financing will be required for continued development and commercialization.
The company expects no product revenue for several years, if ever, and has not yet administered a product candidate to humans. Its principal programs include DSG3-CAART, MuSK-CAART, DSG3/1-CAART and FVIII-CAART. A planned IND submission for MuSK-CAART was anticipated in the second half of 2021.
- COVID-19 did not significantly affect reported second-quarter financial results, but could delay trial enrollment, manufacturing, regulatory activities, supply chains and future financing.
- The company relies substantially on Penn and affiliated entities for research, development, manufacturing and clinical support. The Services Agreement is scheduled to expire no earlier than October 19, 2021, subject to its terms.
- Manufacturing is complex, patient-specific and not yet validated for commercial production. The company expects to transition certain activities to contract development and manufacturing organizations and may incur up to $2.25 million of committed manufacturing spend over the following six months.
- Key clinical and regulatory risks include patient enrollment, clinical holds, adverse events such as cytokine release syndrome and neurotoxicity, uncertain regulatory standards for novel CAAR T-cell therapies, and the possibility that clinical results will not support approval.
- Material commitments include an office lease with approximately $0.6 million of remaining minimum payments at June 30, 2020, the Penn sponsored research commitment, potential Penn milestone payments approaching $20 million if multiple products are successfully developed and launched, and future royalties.
- Management reported effective disclosure controls and procedures and no material change in internal control over financial reporting during the quarter. The company reported no material litigation.
Important facts for investors to verify
- Reconcile the company’s stated liquidity runway of at least the third quarter of 2022 with actual cash burn, clinical-trial spending and future manufacturing commitments.
- Track enrollment, safety findings, dosing progression and FDA feedback from the DesCAARTes Phase 1 trial.
- Assess the timing and cost of transitioning manufacturing from Penn to qualified external manufacturers or internal facilities.
- Review future financing needs, potential equity dilution and the absence of debt or committed financing sources.
- Evaluate the scope, enforceability and continuing obligations under the Penn and CHOP license and research agreements, including milestones and royalties.
- Monitor the impact of COVID-19 and other disruptions on clinical sites, suppliers, regulatory reviews and access to capital.